Efficacy of Nilotinib in First or Second Line Treatment of Primary Melanomas Stage III Unresectable Melanomas.

Clinical trial NCT01168050 · UNKNOWN

Trial details

NCT number: NCT01168050
Sponsor: Assistance Publique - Hôpitaux de Paris
Status: UNKNOWN
Phase: Phase 2
Study type: INTERVENTIONAL

Malignant Skin Melanoma T0 Stage III Melanoma Stage IV Melanoma Amplification

Start date: 2010-07-01
Primary completion: 2013-12-01
Enrollment: 25

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.